Clinical Trial

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT05985798
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China, Lecong Hospital, Shunde District, Foshan, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 258 participants
Start Date 2023-08-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-14